Vanguard Global Advisers
FDMT icon

Vanguard Global Advisers’s 4D Molecular Therapeutics FDMT Stock Holding History

Vanguard Global Advisers’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$201K Sell
15,084
-17,164
-53% -$167K ﹤0.01% 2498
2026
Q1 		$300K Buy
+32,248
New +$281K ﹤0.01% 2240

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Vanguard Global Advisers's FDMT Position: Q2 2026 in Review

Vanguard Global Advisers reduced its 4D Molecular Therapeutics (FDMT) stake by 53% in Q2 2026, selling an estimated $167K and leaving 15,084 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #2498.

Vanguard Global Advisers first reported a position in FDMT in Q1 2026 and has held it in 2 quarters since. The position peaked at $300K in Q1 2026. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Vanguard Global Advisers held 15,084 shares of 4D Molecular Therapeutics worth $201K as of Q2 2026.
  • Vanguard Global Advisers sold 17,164 4D Molecular Therapeutics shares in Q2 2026, an estimated $167K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2498 holding.
  • Vanguard Global Advisers first reported a position in 4D Molecular Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's 4D Molecular Therapeutics position peaked at $300K in Q1 2026.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.